Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 24

of 'Pathophysiology and prediction of chemotherapy-induced nausea and vomiting'

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.
Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR
Expert Opin Pharmacother. 2013 Apr;14(6):757-66.
INTRODUCTION: Nausea and vomiting are two of the most frequent and troubling side effects patients experience during chemotherapy, interfering with compliance with cancer therapies and quality of life. While newly available treatments have improved our ability to manage nausea and vomiting, anticipatory and delayed nausea and vomiting are still major problems for patients receiving chemotherapy. Many cancer patients consider delaying future chemotherapy cycles and some contemplate stopping chemotherapy altogether because of their fear of experiencing further nausea and vomiting.
AREAS COVERED: The purpose of this article is to provide an overview of the pathopsychophysiology of chemotherapy-induced nausea and vomiting (CINV), the recommended guidelines for treatment, and current agents in late-stage clinical trials, and future research needs to address the continued challenges of treatment-related nausea and vomiting.
EXPERT OPINION: Despite advances in pharmaceutical and behavioral therapies, and the provision of standard clinical guidelines for effectively managing CINV, patients continue to experience it. Moreover, control of nausea, acute and delayed, and anticipatory nausea and vomiting remains an important, unmet need among cancer patients. It is critical to focus attention on better understanding the mechanisms underlying nausea, anticipatory symptoms and delayed symptoms.
University of Rochester Medical Center, James P Wilmot Cancer Center, Department of Radiation Oncology, 265 Crittenden Blvd, Box 658, Rochester, NY 14642, USA.